A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-06-30) →
What happened
Ilyang Pharmaceutical disclosed an acquisition of Ilyang Pharmaceutical (Jilin) Co., Ltd., worth US$11.8M.
For context, this deal is worth about 3.9% of the company's own total assets.
| Target | Ilyang Pharmaceutical (Jilin) Co., Ltd. |
|---|---|
| Deal value | US$11.8M |
| vs. company assets | 3.9% |
| Filed | 2026-05-14, Decision to acquire shares/equity in another company |
| Source | DART rcept 20260514801263 → open original filing |
Versions of this filing
- 2026-05-14Original (this page)
- 2026-06-30Amendment 1
Source: DART. Information only, not investment advice.